These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24003078)

  • 1. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.
    Samén E; Arnberg F; Lu L; Olofsson MH; Tegnebratt T; Thorell JO; Holmin S; Stone-Elander S
    J Nucl Med; 2013 Oct; 54(10):1804-11. PubMed ID: 24003078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035.
    Wang H; Yu JM; Yang GR; Song XR; Sun XR; Zhao SQ; Wang XW; Zhao W
    Chin Med J (Engl); 2007 Jun; 120(11):960-4. PubMed ID: 17624262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
    Fozing T; Scheuer C; Samnick S
    Eur J Med Chem; 2010 Sep; 45(9):3780-6. PubMed ID: 20538380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular imaging of epidermal growth factor receptor in glioma-bearing rats].
    Wang H; Yu JM; Song XR; Yang GR; Mu DB; Zhao SQ; Wang XW; Wei L; Liu YL; Song B; Fu Z; Teng XP
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):343-6. PubMed ID: 18953832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro.
    Samén E; Thorell JO; Fredriksson A; Stone-Elander S
    Nucl Med Biol; 2006 Nov; 33(8):1005-11. PubMed ID: 17127174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
    Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
    Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas.
    Sun J; Cai L; Zhang K; Zhang A; Pu P; Yang W; Gao S
    Clin Nucl Med; 2014 Jan; 39(1):e20-6. PubMed ID: 24335566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
    Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
    J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans.
    Liu N; Li M; Li X; Meng X; Yang G; Zhao S; Yang Y; Ma L; Fu Z; Yu J
    J Nucl Med; 2009 Feb; 50(2):303-8. PubMed ID: 19164239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
    Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
    J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
    Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
    Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression.
    Wang H; Yu J; Yang G; Song X; Sun X; Zhao S; Mu D
    Cancer Sci; 2007 Sep; 98(9):1413-6. PubMed ID: 17627611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
    Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
    Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.
    Fredriksson A; Johnström P; Thorell JO; von Heijne G; Hassan M; Eksborg S; Kogner P; Borgström P; Ingvar M; Stone-Elander S
    Life Sci; 1999; 65(2):165-74. PubMed ID: 10416822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
    Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
    Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
    Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
    Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
    Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.